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Abstract
The current state of cancer therapeutics has been moving away from one-size-
fits-all cytotoxic chemotherapy, and towards a more individualized and specific
approach involving the targeting of each tumor’s genetic vulnerabilities. Different
tumors, even of the same type, may be more reliant on certain cellular pathways
more than others. With modern advancements in our understanding of cancer
genome sequencing, these pathways can be discovered. Investigating each of the
millions of possible small molecule inhibitors for each kinase in vitro, however,
would be extremely expensive and time consuming. This project focuses on pre-
dicting the inhibition activity of small molecules targeting 8 different kinases using
multiple deep learning models. We trained fingerprint-based MLPs and simplified
molecular-input line-entry specification (SMILES)-based recurrent neural networks
(RNNs) and molecular graph convolutional networks (GCNs) to accurately predict
inhibitory activity targeting these 8 kinases.
1 Introduction and Background
Cancer continues to be one of the world’s most common and deadly health problems. The American
Cancer Society reports that approximately 1.8 million people will be diagnosed with cancer each year
in the United States, and another 600,000 will succumb to the disease [1]. For patients with cancer,
traditional treatment options including surgery, chemotherapy, and radiation therapy. Each of these
treatments has their own set of side effects, with chemotherapy in particular having poor efficacy and
nontrivial toxicity levels [2].
Modern cancer therapies have started to shift away from this “one-size-fits-all” cytotoxic chemother-
apy approach, and towards a more individualized targeting of specific tumors’ genetic vulnerabilities.
As researchers continue to gain a better understanding of cancer genome sequencing, our understand-
ing of how particular cellular pathways are related to tumorigenics of different types of cancer. In this
paper, we focus on the inhibition of kinases, which are one of the most intensively pursued classes of
proteins for cancer drug discovery. There are approximately 518 kinases encoded within the human
genome, with approximately 30 distinct kinase targets currently being developed for Phase I clinical
trial. Searching for small molecule inhibitors for each kinase would be extremely expensive and time
consuming, but the utilization of machine learning techniques can expedite the process, therefore
allowing for a faster and more accessible approach.
1.1 Types of Kinases
In this paper, we focus on inhibitors of 8 particular protein kinases. They are cyclin-dependent
kinase, epidermal growth factor receptor, glycogen synthase kinase-3 beta, hepatocyte growth factor
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receptor, MAP kinase p38 alpha, tyrosine-protein kinase LCK, tyrosine-protein kinase SRC, and
vascular endothelial growth factor receptor 2. Cyclin-dependent kinases (CDK) are important for the
regulation of various phases and transitions of the cell cycle. CDKs are often the target of tumorigenic
signals that can lead cyclin D to form complexes in the G1/S transition phase of the eukaryotic cell
cycle. Epidermal growth factor receptors (EGFR) are activated by the binding of ligands to the
extra-cellular domain, which leads to signal transduction and activation of various pathways involved
in cell proliferation and survival. EGFR pathway dysregulation is found in multiple human cancers.
For example, overexpression of EGFR is linked to 80 percent of non-small cell lung cancer, and
mutation of EGFR is linked to 20 percent of non-small cell lung cancer [3]. Glycogen synthase
kinase-3 beta (GSK3β) is a protein kinase that has established as a tumor suppressor or promoter in
various cancers such as skin, oral, larynx, breast and other types of cancer. GSK3β is active in resting
cells, and is regulated by various upstream kinases which can cause rapid inhibition or promotion [4].
Hepatocyte growth factor receptors (HGF) are often linked to tumor progression in several cancers
as they have a major role in embryonic organ development and adult organ regeneration. [5] MAP
kinase p38 alpha (MAPK) are stress-activated serine/threonine-specific kinases. MAPK is linked
to diverse cellular functions such as gene expression and cell death. [6] Tyrosine-protein kinase
(LCK) regulates cell growth, migration, and proliferation. Upregulation of LCK is often correlated
with breast cancer [3]. Tyrosine-protein kinase (SRC) is also involved in growth, migration, and
proliferation, but overexpression is linked to colon cancers [3]. Vascular endothelial growth factor
receptor 2 (VEGFR-2) is involved in mediating pro-angiogenic signals. The greater signal intensity
for VEGFR-2 is correlated to human cancer tumors [7].
2 Related Work
Novel approaches to oncology drug discovery has been largely spurred by the new understanding of
how abnormal protein kinase activity has been linked to the development and onset of a variety of
diseases. Different tumors, even of the same type, may be more reliant on certain cellular pathways
more than others, which can be discovered through cancer genome sequencing. Previous research
has been done in order to characterize the structural basis of kinase inhibitor selectivity, and identify
potential kinases that are involved in cancer mechanisms, but there is a lacking of research done to
predict potential inhibitors. Once kinases have been identified, the IC-50 values, SMILES codes,
connectivity, and other features can be utilized in conjunction with deep learning models to predict
the activity of small molecule inhibitors [8].
Briem et al. developed a model using artificial neural networks (ANNs) in order to distinguish
between kinase inhibitors and non-inhibitors for 8 kinases [9]. Their data comprised of 7759 training
kinase inhibitor compounds, with 565 of the molecules classified as "actives" and 7194 classified as
"inactives". A molecule was defined as "active" is it had an IC50 ≤= 10µM in at least 1 out of 8
kinase assays performed in-house. There was also a separate validation test set of 504 molecules,
with 204 "actives" and 300 "inactives". Briem et al. applied a standard feed-forward neural network
through the implementation of the TSAR software package [10]. They generated 13 models, and all
layers were completely connected. By training on their binary dataset and using the majority votes
from the 13 models, they were able to achieve an accuracy score of 0.88, a precision score of 0.84, a
recall score of 0.88, and a F1 score of 0.86. Briem et al. also developed a model based on support
vector machines (SVM), with an accuracy score of 0.88, a precision score of 0.86, a recall score of
0.85, and a F1 score of 0.86. The work done by Briem et al. was the first time that prediction tools
were used to try and capture essential features of kinase inhibitor molecules, as opposed to druglike
molecules that only target particular families. The idea of personalized kinase inhibition is novel, and
Briem et al. were one of the first groups to propose comparing and identifying features of the kinase
inhibitors, rather than predict successful drugs.
More recently, research groups have been interested in learning how to represent the molecular
structure information in a more robust way. While common fingerprinting methods are generally
successful at representing small molecules well, they are non-differentiable and cannot adapt to
emphasize molecular structure aspects differently based on data given. The Pande Group at Stanford
University has been focusing on a new representation of small molecules as undirected graphs of
atoms. Graph convolutional neural networks aim to featurize molecules in a differentiable way, so
that the way the molecule is represented can change based on the data and task given. Riley et al.
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highlights the flexibility of the graph convolution architecture, despite the model performing similar
to fingerprint-based approaches [11].
In our study, we expanded on the work done by Briem et al. by using specific structural features of
the inhibitors, such as SMILES codes and molecular fingerprints, in order to predict which molecules
could serve as inhibitors for various kinases. In addition, we also wanted to explore the GCN
architecture proposed by Pande and Riley et al. Using the various types of data available, we were
able to try a variety of models and approaches and achieve consistent results.
2.1 Dataset
For this project, we utilize the Kaggle Cancer Inhibitors Dataset [12]. It consists of labeled inhibitors
(positive class) and non-inhibitors (negative class) for each of eight kinases. Statistics for the Kaggle
data for each kinase are summarized in Table 1. For each inhibitor, the Kaggle dataset includes a
ChemBL accession ID and binary inhibition label. The vast majority of molecules have labels for
only one of the eight kinases, so it is impractical to perform multitask learning - we train separate
models for each of the eight kinases. We get ChemBL IDs and labels from Kaggle, but we need
feature representations of the molecules to feed into deep learning models. Thus we use the ChemBL
database to gather SMILES strings and the Python RDKit package to generate fingerprints for each
molecules - the SMILES strings and fingerprints will serve as feature representations for the small
molecules
Kinase Total Inhibitors Non-Inhibitors
CDK2 1635 1039 596
EGFR_ERB1 5176 3554 1622
GSK3B 1950 1434 516
HGFR 2145 1830 315
MAP_K_P38A 3597 3080 517
TPK_LCK 1809 1302 507
TPK_SRC 2972 1891 1081
VEGFR2 5123 4089 1034
Table 1: Total, positive (inhibitors), and negative (non-inhibitor) samples for each kinase in Kaggle
dataset
2.2 SMILES
SMILES stands for "simplified molecular-input line-entry system" and is a specification in form of a
line notation for describing the structure of chemical species using short strings that can be understood
for data processing [13]. SMILES strings are unique for each structure. An overview of the SMILES
conversion algorithm starts with the conversion of the SMILES to an internal representation of the
molecular structure and then examines structure and produces a unique SMILES string. SMILES
codes are generated by first breaking the cycles of the molecules, and then writing the branches off a
main backbone. The unique codes are dependent on the bonds chosen to break cycles, on starting
atom used for depth-first traversal, charge, and order in which branches are listed when encountered.
We obtain a unique SMILES string for each small molecule by querying the ChemBL database using
the corresponding ChemBL accession ID provided in the Kaggle dataset.
2.3 Fingerprints
We also choose to represent each small molecule as fingerprints - a unique bit vector corresponding
to the molecule that encode 2D, 3D, and chemical properties. In particular, we use three common
fingerprints - Atom-Pair, Morgan, and Topological Torsion. Atom pairs are a substructure within
each molecule that is defined by the atomic environment and shortest subpath between all pairs of
atoms in the topological representation of a molecule[14]. Atom-pair fingerprints are generated based
on correlations between different atom-pair structures and biological activity. Morgan fingerprints, or
Extended Connectivity fingerprints, are circular fingerprints generated from the topological represen-
tation of the molecule[15]. These fingerprints represent the molecule by the circular neighborhoods
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around each atom. Finally, the Topological Torsion fingerprint is based on sets of four consecutively
connected non-hydrogen atoms, which represent a torsion angle[16]. We generate each of these three
fingerprints using the Python RDKit package by feeding in SMILES string. Each fingerprint is a bit
vector of length 2048, and for each molecule we concatenate the three fingerprints into a bit vector of
length 6144.
2.4 Training, Validation, and Testing Splits
Initially, we randomly split the small molecules for each kinase into training, validation, and testing
with a 0.7:0.15:0.15 ratio. However, in order to make sure that the models do indeed learn novel
chemical features rather than just learn to classify related molecules from the training set, we create
harsher splits using the following approach. For each kinase we cluster the small molecules based
on their concatenated fingerprint vectors into 7 clusters using K-means, randomly select 5 of these
clusters for training, and divide the remaining molecules into validation and testing with a 0.5:0.5
ratio. We include results from both splits.
2.5 Baseline MLP
We will first directly feed the concatenated fingerprint feature representation into a multilayer
perceptron (MLP) with a two hidden dense layers of size 128, each with ReLU activation. Before the
output layer, we include a dropout layer for regularization. The output layer is a dense layer of size 2
- corresponding to the two possible labels - with softmax activation for a probability prediction for
each label. The MLP architecture is summarized in Figure 1a. We use binary cross entropy as the
loss function, as given in the following equation:
J(θ) = −
N∑
i=1
(yi log(yˆi) + (1− yi) log(1− yˆi))
where J is the loss, θ is the current set of model parameters, N is the total number of data samples,
yi is true label (0 or 1) for data sample i, and yi is predicted probability output by the model that
the label for data sample i is 1. Adam is a gradient descent algorithm with an adaptive learning rate
that in practice yields quicker model convergence than vanilla stochastic gradient descent, so we use
Adam to optimize our model [17]. We set the initial learning rate to 0.001, minibatch size to 32, and
dropout probability to 0.5.
2.6 Recurrent Neural Network
To take advantage of the molecular structure and atomic connectivity of the small molecules, we
apply a Recurrent Neural Network (RNN) on the SMILES code of the small molecules. We pad the
SMILES codes of each molecule within a certain kinase dataset with the null character ‘!’ so that each
SMILES code for a particular kinase has equal length for batch train (the codes for different kinases
may have different length). We then convert the SMILES codes to 1-hot vector embeddings. This
is done by first enumerating all the characters that appear in all the SMILES codes for a particular
kinase in an arbitrary order. Then, each character of the SMILES code is converted to a 1-hot vector
that is 1 at the vector index corresponding to the enumeration ID of that character, and 0 at all other
indices. These 1-hot vectors are then fed into a bidirectional Long-term Short-term Memory Network
(LSTM) with 128 hidden units. We use a LSTM because it mitigates the vanishing gradient problem
of standard RNNs [18]. We use a bidirectional LSTM because the atomic connectivity of a molecule
is unordered. The output of the first and last LSTM layers are concatenated into a vector of size 256,
and this vector is fed a dense layer of size 128 with ReLU activation. Before the output layer, we
include a dropout layer for regularization. The output layer is a dense layer of size 2 with softmax
activation for a probability prediction for each label. The RNN architecture is summarized in Figure
1b. Like for the MLP, we use binary cross entropy as the loss function and Adam for gradient descent.
We set the initial learning rate to 0.001, minibatch size to 32, and dropout probability to 0.5. Because
of the exploding gradient problem, we clip the gradient norm to 5.
2.7 Fused Models
To leverage both the chemical features obtained from molecular fingerprints and the structural features
of the SMILES codes, we implement a number of approaches to fuse the fingerprint-based MLP with
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(a) (b)
Figure 1: (a) MLP architecture and (b) RNN architecture
the SMILES-based RNN. The first approach is early fusion, where the outputs of the first and last
pretrained LSTM outputs are concatenated with the fingerprint feature vector to construct a vector
of size 6400. This concatenated vector is then fed as input into the MLP as described in Section
2.5. The early fusion model is illustrated in Figure 2a, and all layers are fine-tuned during training.
The second approach is late fusion, where the output of the final dense layer of size 128 from the
pretrained RNN as described in section 2.6 is concatenated with the output of the final dense layer of
size 128 from the pretrained MLP as described in section 2.5 to produce a vector of size 256. This
vector is then fed through a dropout layer for regularization, and a final output layer of size 2 with
softmax activation to generate probability predictions. The late fusion model is illustrated in Figure
2b, and all layers are fine-tuned during training. Like for the RNN, we use binary cross entropy as
the loss function and Adam for gradient descent. We set the initial learning rate to 0.001, minibatch
size to 32, dropout probability to 0.5, and gradient clipping norm to 5. The final fused model is a
simple ensemble between the MLP and RNN where the predicted probabilities from the two models
are averaged to produce the prediction for the ensemble model.
2.8 Graph Convolutional Neural Networks
In order to perform deep learning on molecules, we must first find a way to featurize the molecule
into a vector, which can then be the input into any neural network. Common methods to featurized
molecules, such as Extended Connectivity Fingerprints (ECFP) and other fingerprinting methods,
are able to represent small molecules well, however, they cannot adapt to the given task, as they are
non-differentiable. Graph convolutional neural networks aim to featurize molecules in a differentiable
way, so that the way the molecule is represented can change based on the task and dataset at hand.
Essentially, a graph convolution layer, similar to a convolutional layer, represents each node as a
combination of its neighbors, as shown in Figure 3. This is accomplished by feeding both atom
features (n-dimensional vectors for each atom) and pair features (n-dimensional vectors for each
pair of atoms) through Weave modules in series[11]. Weave modules combine these atom and pair
features (denoted A and P ) together to generate another set of atom and pair features, which can then
be fed into another Weave module. The architecture of a Weave module is shown in Figure 4, and the
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(a) (b)
Figure 2: (a) RNN+MLP early fusion architecture and (b) RNN+MLP late fusion architecture
definitions of each of the operations is shown below:
A→ A : Ay = f(Ax)
P → P : P y = f(x)
A→ P : P ya,b = g(v1, v2)
v1 = f(A
x
a, A
x
b )
v2 = f(A
x
b , A
x
a)
P → A : Aya = g(v1, v2, v3, . . .)
v1 = f(P
x
a,b)
v2 = f(P
x
a,c)
...
where f is an arbitrary, trainable function and g is an arbitrary commutative function.
For this project, we represented each molecule as an atom feature vector and adjacency graph. These
two matrices were passed through four stacked Weave modules with a max atom size of 100, and fed
the output through a single hidden layer of size 16. We then utilized sigmoid cross-entropy loss to
train. As with the other models, we used the Adam optimizer. Finally, we also ensemble the GCN
with the RNN and MLP by taking the average predicted probabilities across all three models.
3 Results
We independently train each of the models for each of the kinases until the validation loss does not
improve for 20 consecutive epochs. We then generate probability predictions from each of the trained
models on the training, validation, and testing sets, and compute the AU-ROC and mean Average
Precision (mAP). We use AU-ROC because this performance metric is robust to label imbalances,
and we use mAP because in this context, we are particularly interested in the positive class (actual
inhibitors that could serve as potential drugs). The GCN models were only trained and evaluated on
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Figure 3: After each convolution, the feature vectors for each atom represent a weighted average of
its neighbors [19]
Figure 4: Graphic displaying the operations in a Weave module [11]
the cluster-based splits. A GCN model was trained for each kinase except EGFR_ERBB1 (insufficient
training time). RNN+MLP+GCN ensemble predictions were computed and evaluated on the cluster-
based test split for CDK2, HGFR, and MAP_K_P38A ( The performance of each model using random
splits is included in Table 2, and the performance of each model using the cluster-based splits are
included in Table 3. Testing set ROCs and PRCs for each model using random splits are included in
Figure 5 and Figure 6 respectively, and testing set ROCs and PRCs for each model using cluster-based
splits are included in Figure 7 and Figure 8 respectively.
4 Conclusion
In conclusion, we were able to utilize various neural networks to classify small molecules as
inhibiting/non-inhibiting with the random split. For the initial random training-validation-testing split,
the RNN+MLP late fusion model performed the best out of all the algorithms that we tried, with a test
AUROC of > 0.9. As expected, the performance decreased with the harsher cluster-based splits. Sur-
prisingly, on the cluster-based splits, early fusion and RNN+MLP ensembles, rather than RNN+MLP
late fusion, resulted in the best performance. Even with the harsher cluster-based splits, the best
models yielded AUROCs of > 0.7 and mAPs of > 0.8, indicating the models still learn chemically
relevant information to accurately make predictions rather than just learn to classify based on similar
structures from the training set. Moreover, the graph convolution network underperformed compared
to the MLP on the fingerprints, which suggests that the GCN requires further hyperparameter tuning
to match or exceed state of the art methods. However, for TPK_LCK the GCN was the best model,
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Model Train AUC Train mAP Val AUC Val mAP Test AUC Test mAP
CDK2
MLP 0.976 0.985 0.931 0.951 0.931 0.961
RNN 0.946 0.967 0.869 0.899 0.896 0.932
RNN+MLP Early Fusion 0.923 0.951 0.915 0.936 0.903 0.942
RNN+MLP Late Fusion 0.977 0.987 0.919 0.941 0.937 0.965
RNN+MLP Ensemble 0.977 0.986 0.929 0.949 0.932 0.960
EGFR_ERBB1
MLP 0.962 0.982 0.891 0.953 0.883 0.941
RNN 0.903 0.953 0.819 0.917 0.828 0.910
RNN+MLP Early Fusion 0.940 0.971 0.891 0.954 0.876 0.938
RNN+MLP Late Fusion 0.960 0.981 0.895 0.955 0.889 0.945
RNN+MLP Ensemble 0.956 0.979 0.887 0.950 0.883 0.939
GSK3B
MLP 0.983 0.993 0.922 0.967 0.909 0.968
RNN 0.920 0.965 0.833 0.902 0.794 0.900
RNN+MLP Early Fusion 0.976 0.990 0.908 0.965 0.894 0.962
RNN+MLP Late Fusion 0.990 0.996 0.934 0.975 0.917 0.971
RNN+MLP Ensemble 0.974 0.989 0.908 0.960 0.899 0.962
HGFR
MLP 0.978 0.996 0.955 0.990 0.943 0.989
RNN 0.931 0.987 0.881 0.970 0.842 0.951
RNN+MLP Early Fusion 0.991 0.998 0.952 0.989 0.964 0.993
RNN+MLP Late Fusion 0.988 0.998 0.946 0.987 0.954 0.991
RNN+MLP Ensemble 0.981 0.997 0.953 0.990 0.946 0.990
MAP_K_P38A
MLP 0.985 0.997 0.913 0.981 0.923 0.985
RNN 0.959 0.992 0.820 0.963 0.844 0.961
RNN+MLP Early Fusion 0.974 0.995 0.915 0.982 0.931 0.988
RNN+MLP Late Fusion 0.972 0.995 0.917 0.984 0.934 0.988
RNN+MLP Ensemble 0.985 0.997 0.902 0.979 0.903 0.976
TPK_LCK
MLP 0.974 0.987 0.913 0.964 0.942 0.972
RNN 0.916 0.962 0.860 0.935 0.898 0.957
RNN+MLP Early Fusion 0.976 0.990 0.912 0.961 0.941 0.974
RNN+MLP Late Fusion 0.965 0.985 0.914 0.965 0.929 0.961
RNN+MLP Ensemble 0.969 0.986 0.900 0.954 0.945 0.974
TPK_SRC
MLP 0.987 0.992 0.945 0.970 0.941 0.966
RNN 0.910 0.944 0.839 0.910 0.885 0.924
RNN+MLP Early Fusion 0.973 0.985 0.943 0.969 0.920 0.956
RNN+MLP Late Fusion 0.963 0.977 0.938 0.966 0.926 0.957
RNN+MLP Ensemble 0.981 0.989 0.933 0.966 0.943 0.967
VEGFR2
MLP 0.969 0.992 0.893 0.969 0.900 0.968
RNN 0.943 0.985 0.839 0.943 0.836 0.946
RNN+MLP Early Fusion 0.984 0.996 0.900 0.971 0.899 0.968
RNN+MLP Late Fusion 0.971 0.992 0.900 0.971 0.911 0.973
RNN+MLP Ensemble 0.947 0.993 0.895 0.969 0.891 0.966
Table 2: Training, testing, and validation AU-ROC and mAP for each model for each of the 8 kinases
using random splits. Best test set AUCs and mAPs bolded.
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Model Train AUC Train mAP Val AUC Val mAP Test AUC Test mAP
CDK2
MLP 0.937 0.961 0.586 0.716 0.619 0.742
RNN 0.860 0.914 0.694 0.846 0.679 0.803
GCN 0.858 0.908 0.640 0.711 0.637 0.698
RNN+MLP Early Fusion 0.934 0.960 0.628 0.757 0.671 0.782
RNN+MLP Late Fusion 0.939 0.963 0.577 0.703 0.628 0.748
RNN+MLP Ensemble 0.934 0.958 0.681 0.760 0.666 0.784
RNN+MLP+GCN Ensemble 0.933 0.957 0.719 0.783 0.730 0.821
EGFR_ERBB1
MLP 0.933 0.970 0.719 0.854 0.755 0.838
RNN 0.777 0.895 0.723 0.841 0.760 0.827
RNN+MLP Early Fusion 0.924 0.966 0.680 0.834 0.729 0.820
RNN+MLP Late Fusion 0.894 0.953 0.718 0.848 0.773 0.840
RNN+MLP Ensemble 0.920 0.962 0.737 0.864 0.779 0.862
GSK3B
MLP 0.964 0.987 0.815 0.916 0.853 0.943
RNN 0.719 0.877 0.573 0.766 0.523 0.759
GCN 0.717 0.864 0.571 0.709 0.677 0.824
RNN+MLP Early Fusion 0.969 0.988 0.810 0.914 0.844 0.943
RNN+MLP Late Fusion 0.970 0.989 0.814 0.917 0.840 0.933
RNN+MLP Ensemble 0.959 0.984 0.810 0.898 0.839 0.930
HGFR
MLP 0.996 0.999 0.621 0.968 0.639 0.952
RNN 0.717 0.918 0.411 0.924 0.276 0.897
GCN 0.872 0.968 0.463 0.941 0.284 0.897
RNN+MLP Early Fusion 0.990 0.998 0.639 0.965 0.638 0.954
RNN+MLP Late Fusion 0.988 0.997 0.527 0.951 0.522 0.937
RNN+MLP Ensemble 0.992 0.998 0.483 0.938 0.455 0.927
RNN+MLP+GCN Ensemble 0.351 0.913
MAP_K_P38A
MLP 0.989 0.998 0.812 0.971 0.754 0.963
RNN 0.782 0.940 0.636 0.924 0.685 0.937
GCN 0.846 0.959 0.577 0.911 0.532 0.891
RNN+MLP Early Fusion 0.981 0.996 0.819 0.972 0.809 0.975
RNN+MLP Late Fusion 0.981 0.996 0.817 0.974 0.757 0.964
RNN+MLP Ensemble 0.982 0.996 0.821 0.966 0.793 0.967
RNN+MLP+GCN Ensemble 0.732 0.953
TPK_LCK
MLP 0.921 0.967 0.566 0.761 0.627 0.758
RNN 0.749 0.872 0.608 0.759 0.643 0.766
GCN 0.894 0.955 0.684 0.850 0.728 0.832
RNN+MLP Early Fusion 0.927 0.970 0.588 0.775 0.667 0.786
RNN+MLP Late Fusion 0.964 0.986 0.515 0.716 0.604 0.740
RNN+MLP Ensemble 0.915 0.964 0.602 0.727 0.654 0.729
TPK_SRC
MLP 0.952 0.973 0.696 0.793 0.683 0.713
RNN 0.765 0.861 0.573 0.671 0.567 0.580
GCN 0.763 0.841 0.518 0.636 0.518 0.559
RNN+MLP Early Fusion 0.921 0.954 0.677 0.791 0.694 0.732
RNN+MLP Late Fusion 0.922 0.953 0.646 0.763 0.657 0.704
RNN+MLP Ensemble 0.928 0.956 0.668 0.778 0.670 0.705
VEGFR2
MLP 0.963 0.990 0.711 0.908 0.700 0.886
RNN 0.839 0.951 0.698 0.893 0.687 0.888
GCN 0.640 0.863 0.514 0.821 0.574 0.843
RNN+MLP Early Fusion 0.962 0.990 0.723 0.918 0.724 0.907
RNN+MLP Late Fusion 0.960 0.989 0.717 0.909 0.696 0.888
RNN+MLP Ensemble 0.953 0.987 0.754 0.923 0.744 0.906
Table 3: Training, testing, and validation AU-ROC and mAP for each model for each of the 8 kinases
using cluster-based splits. Best test set AUCs and mAPs bolded.
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 5: Testing set ROCs for each model for each of the 8 kinases using random splits.
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 6: Testing set PRCs for each model for each of the 8 kinases using random splits.
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 7: Testing set ROCs for each model for each of the 8 kinases using cluster-based splits.
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 8: Testing set PRCs for each model for each of the 8 kinases using cluster-based splits.
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and for CDK2, the RNN+MLP+GCN model was the best model, so this shows promise that with
further optimization, GCNs can be powerful. Fused models performs the best, so it is a promising
approach to leverage multiple feature representations to optimize classification performance.
4.1 Future Work
First, we can examine the specific chemical features learned by the model by taking model parameter
gradients over features to identify salient features, as well as the biological features of the kinases
that may account for the difference in performance across the kinases. Second, we could also explore
different fingerprints and feature vectors for the MLP and RNN implementation, since different
fingerprints can often have varying amounts of success in different situations. Next, we could start
including the vast amount of unlabeled data from both Kaggle and the CHemBL dataset to begin
semi-supervised learning. Because of the sheer volume of potential small molecules, and the relative
rarity of labeled inhibitors, semi-supervised learning could have immense benefits. In addition, the
CHemBL database has IC50 value information, which means that rather than performing binary
classification, we could explore a regression task, trying to predict IC50 values. Finally, we could
examine the structures of well-performing molecules to determine any commonalities, which could
lead to insight into potential inhibitor classes.
4.2 Incorporating Feedback
We clarified our specific usage of Kaggle dataset, as requested by the peer reviews. Specifically,
we mention we only use the ChemBL IDs and labels from the Kaggle dataset, and extract all other
information from other sources, namely SMILES strings from the ChemBL database and fingerprints
using the Python RDKit package. We also clarified our procedures for generating train/validation/test
splits, and included a more detailed description of SMILES codes as well as how the 1-hot vector
embeddings for the RNN were generated. Moreover, in response to concerns that because we
randomly split the data, various molecular substructures/structural similarities may be shared between
our train, validation, and test sets, thus artificially inflating our validation and test accuracy, we
implemented an additional cluster-based approach to split the data. The fusion models involve
pretraining and augmentation, as suggested by one of the reviews. Moreover, we highlight and
discuss trends with regards to which models perform the best across all the kinases in the conclusion,
and leave to future work some of the suggestions to analyze specific biological features of the kinases
or chemical features of the molecules that may contribute to performance differences. In addition, we
elaborated on previous work done in the realm of inhibitor prediction, and clarified the Briem study.
We have also given statistics for numbers of positively and negatively labeled molecules for each
of the kinases in the kaggle dataset as suggested by reviewers. Finally, we now include both ROCs
(and AUROC) and Precision-Recall curves (and mAP) as visualizations and metrics as suggested by
reviewers.
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